Previous 10 | Next 10 |
-- Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39 th Congress of the European Committee for Treatment and Res...
2023-09-29 15:00:29 ET More on the markets Historical Evidence Between Real Yields Suggests Further Slump For SPY Interest Rates Won't Be Higher For Longer: SPY Implications Rate environment today 'rhymes with 2008' - J.P. Morgan's Kolanovic Stocks in midst o...
-- Additional data presented at ATA 2023 include a subgroup analysis from the TEPEZZA Phase 4 clinical trial and insights on the impact of TED on quality of life (QOL) -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data showing that disrupting the recommended TEPEZZA tre...
Shares of Horizon Therapeutics PLC (NASDAQ: HZNP) traded at a new 52-week high today and are currently trading at $115.7. So far today, approximately 428.53k shares have been exchanged, as compared to an average 30-day volume of 3.65M shares. Horizon Therapeutics PLC, a biotechnology company,...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to U.S. News & World Report’s 2024 list of Best Companies to Work For in the Health Care Industry, ranking among the top companies recognized for employee wellbeing. “We are honored to be named to...
Horizon Therapeutics plc (Nasdaq: HZNP) announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2023 list in the large company category. This is the seventh consecutive year Horizon has been named to the list and the company’s fourth time ranking No. 1. ȁ...
2023-09-19 04:37:07 ET Summary John Paulson's 13F portfolio value decreased by 15% to $1.02B this quarter. The top five positions in Paulson's portfolio are Bausch Health, BrightSphere Investment Group, Perpetua Resources, NovaGold, and Madrigal Pharma. Paulson made new stakes...
2023-09-14 15:00:05 ET Summary Here is an introduction to Sifting the World for new readers. Join, subscribe, or simply follow for a new idea within the next week. Q&A on StW and me as I am launching new, free content shortly. StW One ...
-- Alopecia areata is the second autoimmune indication being evaluated for bempikibart -- Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first pati...
2023-09-12 07:48:40 ET More on Horizon Therapeutics Seeking Alpha’s Quant Rating on Horizon Therapeutics Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion? Improved Outlook For Horizon Therapeutics And Amgen Irish High Court hearing ...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...